Nisha Anand

Biography

Nisha is a strategic, creative and fearless advocate who provides comprehensive advice on Canadian and multi-jurisdictional litigation. She has represented clients before the Ontario Superior Court and Federal Court of Canada in matters related to all aspects of intellectual property.

Nisha’s practice focuses primarily on patent litigation in various industry sectors, including pharmaceuticals, telecommunications, and oil and gas. She also advises clients on intellectual property and litigation strategy, and pharmaceutical clients on regulatory matters with Health Canada.

In the life sciences sector, Nisha has represented both brand and generic companies in patent infringement actions and proceedings under the Patented Medicines (Notice of Compliance) Regulations. Nisha is also recognized for her expertise on Standards-Essential Patents (SEPs) and FRAND issues, with experience litigating several cases in the software and telecommunications sectors dealing with these issues.

A scientist-turned-litigator, Nisha completed a PhD in molecular biology, genetics and cancer at McMaster University prior to obtaining her law degree from the University of Toronto. Nisha is active in the local legal community. She frequently volunteers to speak on panels related to advocacy or intellectual property, judge moots, teach trial advocacy, and to mentor young lawyers.

Representative Cases

• Boehringer Ingelheim (Canada) Ltd. et al v Auro Pharma Inc., T-887-25 and T-1245-25 (2025):
• Bayer Inc. and Regeneron Pharmaceuticals Inc. v Samsung Bioepis Co. Ltd., T-1966-24, T-1968-24, T-1969-24, and T-1970-24 (2024-2025):
• Medexus Pharmaceuticals Inc. et al v. Accord Healthcare Inc. and Intas Pharmaceuticals Ltd., T-1007-20 (2022-2023): Counsel for the defendants in a patent infringement action relating to methotrexate formulations
• The Haudenosaunee Development Institute v. Garlow Media d/b/a/ Two Row Times et al, CV-23-00699171-0000 (2023) Counsel to The Haudenosaunee Development Institute in an action for libel and defamation
• The Incorporated d.b.a. The Tragically Hip v. Trillium Beverage Inc. d.b.a Mill Street Brewery, T-236-21 (2021-2022): Counsel to The Tragically Hip in a trademark and copyright infringement action related to the song name “At the Hundredth Meridian”
• Wi-LAN Inc. v. Apple Inc. et al, T-893-21 (2021-2022): Counsel to Wi-LAN in a patent infringement action involving issues related to Standards Essential Patents (SEPs) and FRAND remedies 
• ViiV Healthcare Company et al. v. Gilead Sciences, Inc., 2020 FC 486, 2021 FCA 122: Counsel to Gilead in a patent infringement action where non-infringement was decided by contested summary trial
• Pliteq Inc. v. Sof Surfaces Inc., CV-18-00611575-0000 (2021-2022): Counsel to Pliteq in an action for trademark infringement and making false and misleading representations under the Trademarks and Competition Acts
• Ecore International Inc. v. Pliteq Inc. T-1479-19 (2020-2021) Co-counsel to Pliteq in a patent infringement action
• Pliteq Inc. v. Ecore International, Inc. T-875-16 (2020-2021): Co-counsel to Pliteq in an action for trademark infringement and making false and misleading representations under the Trademarks and Competition Acts
• Pliteq Inc. v. Ecore International Inc. et al, T-365-20 (2020-2021): Counsel to Pliteq Inc. in a patent infringement action
• Pliteq Inc. v. Wilrep Ltd., T-554-16 (2020-2021): Counsel to Pliteq in an action for trademark infringement and making false and misleading representations under the Trademarks and Competition Acts
• Wi-LAN Inc. v. Bell Mobility Inc., Rogers Communications Canada Inc. and Telus Communications Company, T-303-16, T-304-16 and T-301-16 (2018-2020): Counsel to Wi-LAN in a patent infringement action involving issues related to Standards Essential Patents (SEPs) and FRAND remedies
• Wi-LAN Inc. v. LG Electronics, Inc. et al, T-1349-17 (2017-2020): Counsel to Wi-LAN in a patent infringement action involving issues related to Standards Essential Patents (SEPs) and FRAND remedies  
• Safe Gaming System Inc. v. Atlantic Lottery Corporation et al., 2018 FC 871 (2017): Counsel to Safe Gaming System in a patent infringement action
• Gilead Sciences, Inc. et al. v Apotex Inc. et al., 2016 FC 856: Counsel to Gilead in a proceeding under the Patented Medicines (Notice of Compliance) Regulations
• Gilead Sciences, Inc. v Teva Canada Ltd, T-1888-15 (2015): Counsel to Gilead in a proceeding under the Patented Medicines (Notice of Compliance) regulations and a related patent infringement action
• Apotex Inc. v. Merck Sharp and Dohme Corp., CV-1200-454108-0000 (2015-2017): Counsel to Merck in an action for damages under the Statute of Monopolies and Trademarks Act
• Apotex Inc. v. Pfizer Inc. et al, T-1736-10 (2014-2016): Counsel to Pfizer in a section 8 damages action pursuant to the Patented Medicines (Notice of Compliance) Regulations
• Paladin Labs Inc. v. The Minister of Health and Taro Pharmaceuticals Inc., T-157-16 (2015-2016): Counsel to Paladin Labs in an application for judicial review of a decision by the Minister of Health
• Apotex Inc. v. Hoffman-La Roche Ltd, T-1165-09 (2013-2015): Counsel to Hoffman La-Roche in a section 8 damages action pursuant to the Patented Medicines (Notice of Compliance) Regulations
• Apotex Inc. v. Eli Lilly Canada Inc, T-1321-97 (2013): Counsel to Eli Lilly in a section 8 damages action pursuant to the Patented Medicines (Notice of Compliance) Regulations
• Weatherford Canada Ltd. et al v. Corlac Industries (1998) Ltd. et al, T-1236-01 (2008-2010): Counsel to the defendants in a patent infringement action and the appellants in the subsequent appeal  

Recognition

• Benchmark Litigation – Intellectual Property: Litigation Star
• Best Lawyers in Canada: Intellectual Property Law
• Canadian Lexpert Directory: Intellectual Property – Consistently Recommended  
• Canadian Lexpert Directory: Litigation-Intellectual Property – Consistently Recommended
• Chambers and Partners: Intellectual Property: Litigation – Ranked
• Lexpert Special Edition: Technology & Health – Leading Lawyer
• IAM 1000 – Recommended Individual
• IP Stars – Patent Star
• Who’s Who Legal Canada: Life Sciences – Recommended  
• Whos’ Who Legal Canada: Patents – Recommended  
• Canadian Institute for Health Research Doctoral Research Award (2003-2005)
• Ontario Graduate Scholarship (2003-2004)

Publications

• “Canada: SEPs and FRAND – Litigation, Policy and Latest Developments.” IAM Media (8 Dec 2023)
• “Patented Medicines Notice of Compliance Regulations” Chapter in Life Sciences Law in Canada, 2nd ed. (Carswell)
• “Recent Trends in Canadian Biologics Patent Litigation” FDLI Update, 2014
• “Functional Pharma Claim Flawed, Finds Federal Court of Canada”, APLF IP Law Bugle, 2010
• Thornton S, Anand N, Purcell D, Lee J. (2003) Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med. 81(9): 536-48, 2003
• Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet. Jul; 31(3):301-5.